Rafael Holdings Inc (RFL) News

Form 8-K - Current report

Rafael Holdings, Inc. Announces Proposed Terms of a $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

NEWARK, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-WT...

Form S-3/A - Registration statement under Securities Act of 1933: [Amend]

Form 8-K/A - Current report: [Amend]

Form 8-K - Current report

Rafael Holdings Strengthens its Focus on the Development of Trappsol® Cyclo™ and Announces Chief Executive Officer Bill Conkling Will Be Stepping Down from His Role

Cyclo Therapeutics’ TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick...

Form 4 - Statement of changes in beneficial ownership of securities

Form S-3 - Registration statement under Securities Act of 1933

Form CERT - Certification by an exchange approving securities for listing

Form 8-K - Current report

Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals

NEWARK, N.J. and GAINESVILLE, Fla., March 26, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), and...

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-A12B - Registration of securities [Section 12(b)]

Rafael Holdings Reports Second Quarter Fiscal 2025 Financial Results

The planned merger with Cyclo Therapeutics is anticipated to close in Q3 pending shareholder approvals...